Is it Good Time to Bail on Cellectar Biosciences Inc. [CLRB]? Let’s Look at the Charts

Cellectar Biosciences Inc. [CLRB] has traded in a range of $1.01 to $3.33 in the last 1 year. As of this writing, the stock is at $1.51, up 20.24%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, CLRB shares are 24.18% up with the monthly amount drift of 32.89% and seems well in a long time frame.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 9, November 2020, Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update. According to news published on Yahoo Finance, Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Analyst Birdseye View:

The most recent analyst activity for Cellectar Biosciences Inc. [NASDAQ:CLRB] stock was on January 21, 2020, when it was Resumed with a Buy rating from ROTH Capital, which also raised its 12-month price target on the stock to $10. On September 13, 2019, ROTH Capital Initiated a Buy rating. On December 21, 2016, Ladenburg Thalmann Initiated a Buy rating and increased its price target to $2.70.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.01 and a peak of $3.33. Right now, the middling Wall Street analyst 12-month amount mark is $5.50. At the most recent market close, shares of Cellectar Biosciences Inc. [NASDAQ:CLRB] were valued at $1.51.


The Principal structure of this organization shows its whole liability to whole principal at 5.50 and the whole liability to whole assets at 4.31. It shows enduring liability to the whole principal at 4.40 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.2067 points at 1st support level, the second support level is making up to 0.8983. But as of 1st resistance point, this stock is sitting at 1.7967 and at 2.0783 for 2nd resistance point.

Cellectar Biosciences Inc. [CLRB] reported its earnings at -$0.15 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.2/share signifying the difference of 0.05 and 25.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.26 calling estimates for -$0.3/share with the difference of 0.04 depicting the surprise of 13.30%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Cellectar Biosciences Inc. [NASDAQ:CLRB] is 5.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.83. Now if looking for a valuation of this stock’s amount to book ratio is 2.67.

Insider Stories

The most recent insider trade was by Elefant Dov, Chief Financial Officer, and it was the purchase of 4348.0 shares on Jun 05. Longcor Jarrod, the Chief Business Officer, completed a purchase of 65218.0 shares on Jun 05. On Jun 05, CARUSO JAMES V, President and CEO, completed a purchase of 21740.0 shares.